151 related articles for article (PubMed ID: 35414435)
1. Haematological actions of androgens.
Warren AM; Grossmann M
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101653. PubMed ID: 35414435
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.
Gagliano-Jucá T; Pencina KM; Ganz T; Travison TG; Kantoff PW; Nguyen PL; Taplin ME; Kibel AS; Li Z; Huang G; Edwards RR; Nemeth E; Basaria S
Am J Physiol Endocrinol Metab; 2018 Dec; 315(6):E1185-E1193. PubMed ID: 30325657
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
Decensi A; Torrisi R; Fontana V
Br J Cancer; 1994 Mar; 69(3):617-9. PubMed ID: 8123500
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
5. Androgens and depression: a review and update.
Nead KT
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):175-179. PubMed ID: 30958398
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study.
Tan WS; Low WY; Ng CJ; Tan WK; Tong SF; Ho C; Khoo EM; Lee G; Lee BC; Lee V; Tan HM
BJU Int; 2013 Jun; 111(7):1130-40. PubMed ID: 23651425
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
Gulley JL; Aragon-Ching JB; Steinberg SM; Hussain MH; Sartor O; Higano CS; Petrylak DP; Chatta GS; Arlen PM; Figg WD; Dahut WL
J Urol; 2008 Oct; 180(4):1432-7; discussion 1437. PubMed ID: 18710748
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
9. Androgens and prostate cancer; pathogenesis and deprivation therapy.
Grossmann M; Cheung AS; Zajac JD
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
11. Testosterone Administration During Energy Deficit Suppresses Hepcidin and Increases Iron Availability for Erythropoiesis.
Hennigar SR; Berryman CE; Harris MN; Karl JP; Lieberman HR; McClung JP; Rood JC; Pasiakos SM
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31894236
[TBL] [Abstract][Full Text] [Related]
12. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
Denmeade SR; Isaacs JT
Prostate; 2010 Oct; 70(14):1600-7. PubMed ID: 20607766
[TBL] [Abstract][Full Text] [Related]
13. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Shiota M; Endo S; Fujimoto N; Tsukahara S; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Eto M
Urol Oncol; 2020 Nov; 38(11):849.e11-849.e18. PubMed ID: 32712140
[TBL] [Abstract][Full Text] [Related]
15. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
16. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
[TBL] [Abstract][Full Text] [Related]
17. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point.
Bachman E; Travison TG; Basaria S; Davda MN; Guo W; Li M; Connor Westfall J; Bae H; Gordeuk V; Bhasin S
J Gerontol A Biol Sci Med Sci; 2014 Jun; 69(6):725-35. PubMed ID: 24158761
[TBL] [Abstract][Full Text] [Related]
18. Testosterone therapy and prostate cancer--safety concerns are well founded.
Klotz L
Nat Rev Urol; 2015 Jan; 12(1):48-54. PubMed ID: 25563848
[TBL] [Abstract][Full Text] [Related]
19. Testosterone action on erythropoiesis does not require its aromatization to estrogen: Insights from the testosterone and estrogen treatment of two aromatase-deficient men.
Rochira V; Zirilli L; Madeo B; Maffei L; Carani C
J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):189-94. PubMed ID: 19159688
[TBL] [Abstract][Full Text] [Related]
20. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
